EUVIMEDEUVIMED entdecken
Crossref

Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer

Li-Zhi Cheng iD, Dan-Ling Huang, Zhang-Rui Tang, Jia-Hao Zhang, Ting Xiong, Chen Zhou, Nai-Xia Zhang, Rong Fu, Yong-Xian Cheng, Zhao-Qiu Wu iD

British Journal of Pharmacology · 2023-12 · 180 (23) · 3071-3091

DOI: 10.1111/bph.16193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 18.08.2023. Verfasst von Li-Zhi Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shenzhen Fundamental Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The scaffold molecule Axin2 is constitutively activated in colorectal cancer (CRC) and functions as a potent promoter of CRC behaviour. Pharmacological targeting of Axin2 may therefore exert a therapeutic effect in patients with CRC. Here, we discovered a potent small‐molecule inhibitor of Axin2, based on the mechanism by which Axin2 is regulated post‐translationally, and investigated its antitumour effects. Experimental Approach Compound discovery and its inhibitory action on Axin2 protein were revealed by microscale thermophoresis, in vitro kinase assay, quantitative kinetic assay, immunoblotting/immunoprecipitation, RT‐qPCR and cycloheximide pulse‐chase assay. Compound antitumour effects and the underlying mechanisms were evaluated in multiple cell‐based assays and mouse models. Key Results We discovered that glycogen synthase kinase 3β (GSK3β) phosphorylates Axin2 at two consensus motifs and coupled Axin2 phosphorylation to its ubiquitination (mediated by the E3 ligase β‐Trcp2) and proteasomal degradation. The binding of Axin2 to GSK3β in CRC cells is faint, which enables most of the Axin2 protein to maintain an unphosphorylated status and thereby permits the cells to preserve high levels of Axin2. Importantly, we identified a small‐molecule compound CW85319 that enhances Axin2's interaction with GSK3β via forming a high affinity for Axin2. Treatment of CRC cells with CW85319 enhanced Axin2 binding with GSK3β, thereby promoting Axin2 phosphorylation, subsequent ubiquitination, and degradation. Furthermore, we demonstrated that CW85319 efficiently suppressed Axin2‐driven CRC growth and metastasis, without eliciting side toxicity. Conclusions and Implications These findings suggest that pharmacological targeting of Axin2 by CW85319 may provide therapeutic benefits against certain human cancers, especially CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsMiceAnimalsHumansCell Line, TumorGlycogen Synthase Kinase 3 betaDisease Models, AnimalImmunoblottingAxin Protein

Stichwörter der Autor:innen

GSK3β-Axin2 interactionSnailcolorectal cancer progressionsmall-molecule inhibitorβ-Trcp2

Substanzen

Glycogen Synthase Kinase 3 betaAxin2 protein, mouseAxin Protein

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Institute for Inheritance-Based Innovation of Chinese Medicine, School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

ORCID-Profile: Li-Zhi Cheng, Zhao-Qiu Wu

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Shenzhen Fundamental Research Program
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Cheng, L. Z., Huang, D. L., Tang, Z. R., Zhang, J. H., Xiong, T., Zhou, C., Zhang, N. X., Fu, R., Cheng, Y. X., & Wu, Z. Q. (2023). Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer. British Journal of Pharmacology, 180(23), 3071-3091. https://doi.org/10.1111/bph.16193

Vancouver

Cheng LZ, Huang DL, Tang ZR, Zhang JH, Xiong T, Zhou C, et al. Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer. British Journal of Pharmacology. 2023;180(23):3071-3091. doi:10.1111/bph.16193

BibTeX
@article{Cheng2023,
  author = {Cheng, Li-Zhi and Huang, Dan-Ling and Tang, Zhang-Rui and Zhang, Jia-Hao and Xiong, Ting and Zhou, Chen and Zhang, Nai-Xia and Fu, Rong and Cheng, Yong-Xian and Wu, Zhao-Qiu},
  title = {Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer},
  journal = {British Journal of Pharmacology},
  year = {2023},
  volume = {180},
  number = {23},
  pages = {3071--3091},
  doi = {10.1111/bph.16193}
}
Kostenlos starten →